Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy

Background: To characterize humoral response after standard anti-SARS-CoV-2 vaccination in Rituximab-treated patients and to determine the optimal time point after last Rituximab treatment for appropriate immunization. Methods: Sixty-four patients who received Rituximab within the last seven years p...

Descripción completa

Detalles Bibliográficos
Autores principales: Töllner, Maximilian, Speer, Claudius, Benning, Louise, Bartenschlager, Marie, Nusshag, Christian, Morath, Christian, Zeier, Martin, Süsal, Caner, Schnitzler, Paul, Schmitt, Wilhelm, Bergner, Raoul, Bartenschlager, Ralf, Lorenz, Hanns-Martin, Schaier, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952324/
https://www.ncbi.nlm.nih.gov/pubmed/35330069
http://dx.doi.org/10.3390/jcm11061739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952324/
https://www.ncbi.nlm.nih.gov/pubmed/35330069
http://dx.doi.org/10.3390/jcm11061739

Ejemplares similares